Cholestasis, including primary biliary cirrhosis (PBC) and primary sclerosing cholangitis
(PSC), results from an impairment or disruption of bile production and causes intracellular …

Cholestatic liver diseases result from gradual destruction of bile ducts, accumulation of bile
acids and self-perpetuation of the inflammatory process leading to damage to …

Background Effective treatments for patients with primary biliary cholangitis are limited.
Seladelpar, a peroxisome proliferator–activated receptor delta agonist, has potential …

OBJECTIVES: The aim of this study was to assess the long-term prognosis, efficacy, and
safety of combination therapy using ursodeoxycholic acid (UDCA) and bezafibrate (BF) for …

Background and aim Off‐label use of fibrates in patients with cholestatic liver diseases
results in improved biochemical parameters and pruritus; however, their safety in this …

Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases - Clinics in Liver Disease Skip
to Main Content Advertisement Clinics in Liver Disease Log in Register Log in Subscribe Claim …

The accumulation of bile acids in the liver leads to the development of cholestasis and
hepatocyte injury. Nuclear receptors control the synthesis and transport of bile acids in the …

Background Ursodeoxycholic acid (UDCA) is the first‐line therapy for primary biliary
cholangitis (PBC). However, nearly 40% of patients have an incomplete response to UDCA …

Fibrates, which are agonists of peroxisome proliferator-activated receptor alpha, have
received increasing attention in the treatment of primary biliary cholangitis. Reduced …

Background Bezafibrate (BZF) alone or in combination with ursodeoxycholic acid (UDCA)
has been used to slow disease progression in patients with primary biliary cholangitis …